Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes

RS Busch, MP Kane - Postgraduate medicine, 2017 - Taylor & Francis
Among persons with type 2 diabetes (t2d), the development of glucose intolerance involves
dysfunction in several organs and tissues, including the muscle, liver, pancreas, kidney …
被引用次数：70 相关文章

Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes

RS Busch, MP Kane - Postgraduate medicine, 2017 - pubmed.ncbi.nlm.nih.gov
Among persons with type 2 diabetes (t2d), the development of glucose intolerance involves
dysfunction in several organs and tissues, including the muscle, liver, pancreas, kidney …

[引用][C] Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes

RS Busch, MP Kane - Postgraduate Medicine, 2017 - cir.nii.ac.jp
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary
approach to the treatment of type 2 diabetes | CiNii Research CiNii 国立情報学研究所 学術情報 …

Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.

RS Busch, MP Kane - Postgraduate Medicine, 2017 - europepmc.org
Among persons with type 2 diabetes (t2d), the development of glucose intolerance involves
dysfunction in several organs and tissues, including the muscle, liver, pancreas, kidney …